Last CNY8.95 CNY
Change Today -0.27 / -2.93%
Volume 15.6M
As of 2:05 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

yabao pharmaceutical group-a (600351) Snapshot

Open
CNY9.22
Previous Close
CNY9.22
Day High
CNY9.22
Day Low
CNY8.89
52 Week High
10/16/14 - CNY11.08
52 Week Low
12/23/13 - CNY5.77
Market Cap
6.2B
Average Volume 10 Days
13.1M
EPS TTM
CNY0.23
Shares Outstanding
692.0M
EX-Date
07/14/14
P/E TM
39.6x
Dividend
CNY0.06
Dividend Yield
0.67%
Current Stock Chart for YABAO PHARMACEUTICAL GROUP-A (600351)

Related News

No related news articles were found.

yabao pharmaceutical group-a (600351) Related Businessweek News

No Related Businessweek News Found

yabao pharmaceutical group-a (600351) Details

Yabao Pharmaceutical Group Co., Ltd, a specialty pharmaceutical company, is engaged in the research and development, manufacture, and operation of western and Chinese medicines, APIs, health care products, and packing materials for medicines in China and internationally. The company’s marketed products are in cardiovascular, oncology, pediatric, and women’s health areas; and research and development programs in diabetes, inflammation, and cerebrovascular areas. It also provides finished drug products in various forms, such as tablets, injections, capsules, granules, and suppositories, as well as in powders for injections; and TCM products. In addition, the company is involved in planting and processing medicinal herbs; and producing packing material for medicine, such as plastic bottles, adhesive labels, bottles cushions, carton boxes, cartons etc. Yabao Pharmaceutical Group Co., Ltd was founded in 1978 and is based in Yuncheng, China.

Founded in 1978

yabao pharmaceutical group-a (600351) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

yabao pharmaceutical group-a (600351) Key Developments

Yabao Pharmaceutical Group Co., Ltd(SHSE:600351) added to Shanghai Stock Exchange Health Care Sector Index

Yabao Pharmaceutical Group Co., Ltd will be added to the Shanghai Stock Exchange Health Care Sector Index.

Yabao Pharmaceuticals Partners with MRC Technology

MRC Technology and Yabao Pharmaceuticals Group Co. Ltd. have announced a license agreement to discover, develop and commercialize compounds targeting a specific kinase involved in neurodegeneration, with the aim of developing novel therapeutics for the treatment of Parkinson's disease. Under the terms of the agreement, Yabao receives exclusive rights to discover, develop and commercialize the therapeutics in China, Taiwan and Hong Kong, while MRC retains rights in all other markets.

Yabao Pharmaceutical Group Co., Ltd Announces Earnings Results for the Nine Months of 2014

Yabao Pharmaceutical Group Co. Ltd. announced earnings results for the nine months of 2014. For the period, the company reported basic earning per share of CNY 0.20 and weighted average return on net assets of 8.06%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600351:CH CNY8.95 CNY -0.27

600351 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600351.
View Industry Companies
 

Industry Analysis

600351

Industry Average

Valuation 600351 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 40.3x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact YABAO PHARMACEUTICAL GROUP-A, please visit www.yabao.com.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.